What question did this study set out to answer?

April 21, 2026Open Access

Real-World Description of Non-ICANS Neurologic Events Among Patients with Relapsed or Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel Using Two Large US Databases

Key Points

To describe non-ICANS neurologic events in patients with relapsed or refractory multiple myeloma treated with ciltacabtagene autoleucel.
Analyzed data from two large US databases
Compared rates of neurologic events post-infusion to prior trials
Assessed real-world treatment outcomes
Rates of non-ICANS neurologic events were comparable or lower than previous trials
Supports the favorable risk-benefit profile of ciltacabtagene autoleucel for routine use

Abstract

In this real-world study, rates of non-ICANS NEs post-cilta-cel infusion across two databases were comparable to or lower than prior trials or real-world studies, reinforcing the favorable risk-benefit profile of cilta-cel in routine practice. Graphical Abstract available for this article.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

Sidana et al. (Sat,) studied this question.

www.synapsesocial.com/papers/69e7138bcb99343efc98cfbc — DOI: https://doi.org/10.1007/s40487-026-00433-y

Authors

Surbhi Sidana

Saurabh P. Nagar

Sabyasachi Ghosh

Journals

Oncology and Therapy

Actions

Institutions

Stanford University

Johnson & Johnson (United States)

Mayo Clinic Hospital

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Real-World Description of Non-ICANS Neurologic Events Among Patients with Relapsed or Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel Using Two Large US Databases

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Cite this study

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion